



Sensipar[®] (cinacalcet) – First-time generic

- On March 12, 2019, [Piramal announced](#) that Slate Run Pharmaceuticals launched an [AB-rated](#) generic version of Amgen's [Sensipar \(cinacalcet\)](#) tablets.
 - In addition, [Aurobindo](#), [Cipla](#), [Strides](#), [Sun](#), [Mylan](#) and [Teva](#) have received FDA approval of AB-rated generic versions of Sensipar.
 - Launch plans for these additional generics are pending.
- Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; and hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.